Mesenchymal stem cells (MSCs) possess tumor-tropic properties and consequently have been used to deliver therapeutic agents for cancer treatment. Their potential in cancer therapy highlights the need for a consistent and renewable source for the production of uniform human MSCs suitable for clinical applications. In this study, we seek to investigate whether human embryonic stem cells can be used as a cell source to fulfill this goal. We generated MSC-like cells from two human embryonic stem cell lines, HuES9 and H1, and observed that MSC-like cells derived from human embryonic stem cells were able to migrate into human glioma intracranial xenografts after being injected into the cerebral hemisphere contralateral to the tumor inoculation site. We engineered these cells with baculoviral and lentiviral vectors, respectively, for transient and stable expression of the herpes simplex virus thymidine kinase gene. In tumor-bearing mice the engineered MSC-like cells were capable of inhibiting tumor growth and prolonging survival in the presence of ganciclovir after they were injected either directly into the xenografts or into the opposite hemisphere. Our findings suggest that human embryonic stem cell-derived MSCs may be a viable and attractive alternative for large-scale derivation of targeting vehicles for cancer therapy.
Get full access to this article
View all access options for this article.
References
1.
AhmedA.U., RolleC.E., TylerM.A.et al.2010. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol. Ther., 18:1846–1856.
2.
ArpornmaeklongP., BrownS.E., WangZ., KrebsbachP.H.2009. Phenotypic characterization, osteoblastic differentiation, and bone regeneration capacity of human embryonic stem cell-derived mesenchymal stem cells. Stem Cells Dev., 18:955–968.
3.
AsklundT., AppelskogI.B., AmmerpohlO.et al.2003. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp. Cell Res., 284:185–195.
4.
BakX.Y., YangJ., WangS.2010. Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy. Cancer Gene Ther., 17:721–729.
5.
BalaniP., BoulaireJ., ZhaoY.et al.2009. High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol. Ther., 17:1003–1011.
6.
BexellD., GunnarssonS., TorminA.et al.2009. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther., 17:183–190.
ChuangC.K., WongT.H., HwangS.M.et al.2009. Baculovirus transduction of mesenchymal stem cells: In vitro responses and in vivo immune responses after cell transplantation. Mol. Ther., 17:889–896.
9.
DuJ., ZengJ., ZhaoY.et al.2010. The combined use of viral transcriptional and post-transcriptional regulatory elements to improve baculovirus-mediated transient gene expression in human embryonic stem cells. J. Biosci. Bioeng., 109:1–8.
10.
GaoY., YaoA., ZhangW.et al.2010. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene, 29:2784–2794.
11.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM.et al.2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.
12.
HallB., AndreeffM., MariniF.2007. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb. Exp. Pharmacol., 180:263–283.
13.
HuY.C.2008. Baculoviral vectors for gene delivery: A review. Curr. Gene Ther., 8:54–65.
14.
HwangN.S., VargheseS., LeeH.J.et al.2008. In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc. Natl. Acad. Sci. U.S.A., 105:20641–20646.
15.
KernS., EichlerH., StoeveJ.et al.2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
16.
KloppA.H., SpaethE.L., DembinskiJ.L.et al.2007. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res., 67:11687–11695.
17.
KucerovaL., AltanerovaV., MatuskovaM.et al.2007. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res., 67:6304–6313.
LeeD.H., AhnY., KimS.U.et al.2009. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin. Cancer Res., 15:4925–4934.
20.
LianQ., LyeE., Suan YeoK.et al.2007. Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs. Stem Cells, 25:425–436.
21.
LiuH., DowE.C., AroraR.et al.2006. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes. J. Virol., 80:7765–7768.
22.
LiuY.P., SeckinH., IzciY.et al.2009. Neuroprotective effects of mesenchymal stem cells derived from human embryonic stem cells in transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab., 29:780–791.
23.
LoW.H., HwangS.M., ChuangC.K.et al.2009. Development of a hybrid baculoviral vector for sustained transgene expression. Mol. Ther., 17:658–666.
24.
LoebingerM.R., KyrtatosP.G., TurmaineM.et al.2009a. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res., 69:8862–8867.
25.
LoebingerM.R., EddaoudiA., DaviesD., JanesS.M.2009b. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res., 69:4134–4142.
26.
MenonL.G., PicinichS., KoneruR.et al.2007. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells, 25:520–528.
27.
MenonL.G., KellyK., YangH.W.et al.2009. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells, 27:2320–2330.
28.
MesnilM., YamasakiH.2000. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res., 60:3989–3999.
29.
MileticH., FischerY., LitwakS.et al.2007. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol. Ther., 15:1373–1381.
30.
NakamizoA., MariniF., AmanoT.et al.2005. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 65:3307–3318.
31.
NakamuraK., ItoY., KawanoY.et al.2004. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther., 11:1155–1164.
32.
NethP., CiccarellaM., EgeaV.et al.2006. Wnt signaling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells, 24:1892–1903.
33.
PauwelsK., GijsbersR., ToelenJ.et al.2009. State-of-the-art lentiviral vectors for research use: Risk assessment and biosafety recommendations. Curr. Gene Ther., 9:459–474.
34.
PerdikogianniC., DimitriouH., StiakakiE.et al.2008. Could cord blood be a source of mesenchymal stromal cells for clinical use?Cytotherapy, 10:452–459.
35.
PittengerM.F., MackayA.M., BeckS.C.et al.1999. Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
36.
RiesC., EgeaV., KarowM.et al.2007. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood, 109:4055–4063.
SchichorC., BirnbaumT., EtminanN.et al.2006. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC)Exp. Neurol., 199:301–310.
39.
SchroderA.R., ShinnP., ChenH.et al.2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110:521–529.
40.
SonabendA.M., UlasovI.V., TylerM.A.et al.2008. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells, 26:831–841.
41.
StraussR., HüserA., NiS.et al.2007. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol. Ther., 15:193–202.
42.
TimmersL., LimS.K., ArslanF.et al.2007. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res., 1:129–137.
43.
TrivediP., HemattiP.2008. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp. Hematol., 36:350–359.
44.
TylerM.A., UlasovI.V., SonabendA.M.et al.2009. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther., 16:262–278.
45.
WangS., BalasundaramG.2010. Potential cancer gene therapy by baculoviral transduction. Curr. Gene Ther., 10:214–225.
46.
YenB.L., ChangC.J., LiuK.J.et al.2009. Brief report: Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells, 27:451–456.
47.
YuJ.M., JunE.S., BaeY.C., JungJ.S.2008. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev., 17:463–473.
48.
ZengJ., DuJ., ZhaoY.et al.2007. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells, 25:1055–1061.
49.
ZengJ., DuJ., LinJ.et al.2009. High-efficiency transient transduction of human embryonic stem cell-derived neurons with baculoviral vectors. Mol. Ther., 17:1585–1593.
50.
ZhangX., XuW., QianH.et al.2011. Mesenchymal stem cells modified to express lentivirus-TNFα-Tumstatin inhibit the growth of prostate cancer. J. Cell. Mol. Med., 15:433–444.
51.
ZhaoY., WangS.2010. Human NT2 neural precursor-derived tumor-infiltrating cells as delivery vehicles for treatment of glioblastoma. Hum. Gene Ther., 21:683–694.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
